Aerie Pharmaceuticals — Investor Presentation (January 2021)
25 slides from Aerie Pharmaceuticals's investor presentation, Jan 19, 2021

Slide 1: Company Overview Investor Presentation January 2021
Company Overview Investor Presentation January 2021 Exhibit 99.1

Slide 2: Important Information
For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified

Slide 3: Aerie Overview
Aerie Overview Rhopressa® and Rocklatan® have not been approved by any regulatory authority other than the FDA and EMA. AR-13503 and AR-1105 are development stage product candidates and are not approved by any regulatory agency. Aerie IOP–Reducing Products (IP 2030+) Key Pipeline Opportunities AR-15

Slide 4: Aerie Overview: U.S. Glaucoma Market
Aerie Overview For Investor Use Sources: IQVIA: NPA Rx and NSP Unit data Graph Source: IQVIA 2019 CAI: Carbonic Anhydrase Inhibitor AA: Alpha Agonist BB: Beta Blocker Estimated Glaucoma Market TRx Mix - ~$3B Market, 36M TRx, 55M bottles - 55% of unit volume first-line (PGAs) - 45% of unit volume 2-3

Slide 5: Glaucoma Commercialization Focus
Glaucoma Commercialization Focus Ongoing communication of the MOST Data and coverage via various communication channels Rhopressa® Coverage: 90% Commercial, 89% Med D Rocklatan® Coverage: 89% Commercial, 56% Med D plus 15% Low Income Subsidy Continued execution of the Pulse Strategy, focused on driv

Slide 6: Topline Results from Rhopressa Multi-center Open-label Study (MOST)
Topline Results from Rhopressa® Phase 4 Multi-center Open-label Study (MOST) 12-week MOST study evaluated efficacy, tolerability and safety of Rhopressa® use in 260 patients in a real-world clinical setting Use of Rhopressa® as monotherapy or adjunct was at discretion of the physician Used adjunctiv

Slide 7: U.S. Glaucoma Franchise Update
For Investor Use U.S. Glaucoma Franchise Update Record Sales Out in December 2020: 104,233 Bottles Rhopressa® and Rocklatan® have not been approved by any regulatory authority other than the FDA and EMA. Actual Weekly Sales-Out to Pharmacies Data as of 1/8/2021 IQVIA Weekly Data as of 1/8/2021 1/4/2

Slide 8: Advancing the Pipeline
For Investor Use Advancing the Pipeline Drug/Target Indication Development Stage Preclinical Phase 1/2a Phase 2b Front of the Eye AR-15512 (TRPM8 agonist) Dry Eye Back of the Eye AR-1105 Implant (Dexamethasone) RVO/DME AR-13503 Implant (ROCK, PKC) wAMD DME/DR Glaucoma Neuro- enhancement

Slide 9: U.S. Dry Eye Market: Under-diagnosed and Under-treated
For Investor Use U.S. Dry Eye Market: Under-diagnosed and Under-treated Estimated 30 million dry eye sufferers in the United States; less than 3 million treated Dry eye related symptoms are one of the most common reasons for patients to visit an eye care professional Represents a significant health

Slide 10: AR-15512 for Dry Eye: Novel Mechanism of Action
AR-15512 for Dry Eye Novel Mechanism of Action – Modulation of Corneal TRPM8 receptors Topical eye drop TRPM8 receptor is a cold thermoreceptor ion channel located on corneal nerve endings Reduced corneal temperature triggered by tear evaporation activates TRPM8 which leads to: Increased basal tear

Slide 11: AR-15512 (TRPM8 Agonist) for Dry Eye: How AR-15512 works
AR-15512 (TRPM8 Agonist) for Dry Eye For Investor Use How AR-15512 works AR-15512 Ophthalmic Solution

Slide 12: AR-15512 for Dry Eye: Phase 2a Study
AR-15512 for Dry Eye Avizorex completed a Phase 2a study in early 2019 in 109 subjects One concentration (0.0014%) and two dosing regimens (BID/TID) for 4 weeks were evaluated Primary endpoint: % of patients ≥ 20 points change in symptoms questionnaire (SANDE) Secondary endpoints: Schirmer’s test (t

Slide 13: Significant efficacy achieved for sign and symptoms with BID dosing
Significant efficacy achieved for sign and symptoms with BID dosing of 0.0014% (50µM) AVX-012 (AR-15512) over 28 days For Investor Use ++Data on File Symptoms: SANDE Score Percentage of patients improving ≥20 score p=0.1 p=0.021 Graph on the right represents primary endpoint with a subset of more se

Slide 14: AVX-012 (AR-15512) Dry Eye Clinical Trial Highlights: Schirmer
++Data on File For Investor Use AVX-012 (AR-15512) Dry Eye Clinical Trial Highlights Sign: Schirmer Evaluation Percentage of patients improving ≥3mm Significant efficacy achieved for sign and symptoms with BID dosing of 0.0014% (50µM) AVX-012 (AR-15512) over 28 days

Slide 15: Dry Eye Program: AR-15512
For Investor Use Dry Eye Program: AR-15512 Target symptoms: significant step in addressing the symptoms of dry eye patients and providing a cooling sensation Impact basal tear production: production of natural tears and not just an acute reflex tear Safe for long-term use Other approved products on

Slide 16: AR-15512: COMET-1 Phase 2b Underway
For Investor Use AR-15512: COMET-1 Phase 2b Underway Clinical Trial Series named “COMET” = Cold Thermoreceptor Modulation as an Effective Treatment Phase 2b clinical study commenced October 2020 Phase 2b study is evaluating efficacy and safety of 0.0014% and 0.003% BID 360 patients (1:1:1) for 3 mon

Slide 17: 2019 U.S. Retinal Disease Market
For Investor Use 2019 U.S. Retinal Disease Market Sources: Mixture of public information, IQVIA, Market-Scope and estimates – Feb 2020 2019 Sales: $6.8B 2019 Unit Sales: 8.1MM

Slide 18: Sustained-Release Retinal Implant Product Candidates
For Investor Use Sustained-Release Retinal Implant Product Candidates AR-1105 (Dexamethasone) Implant (Positive Topline Phase 2 results, Phase 3 plans underway for the U.S. and Europe) Indications under development: retinal vein occlusion (RVO) and DME Target product profile vs. Ozurdex® Designed fo

Slide 19: AR-1105: Phase 2 Topline Summary
AR-1105: Phase 2 Topline Summary The Phase 2 clinical trial (AR-1105-CS201) was conducted at 19 centers in the United States. A total of 49 patients completed the study. The objective of the Phase 2 clinical trial was to evaluate two formulations of AR-1105, clinical formulation #1 (CF-1) and clinic

Slide 20: AR-1105: Opportunity Considerations
AR-1105: Opportunity Considerations The Diabetic Macular Edema market is expected to grow with increasing diabetes prevalence in the United States and abroad. The performance of AR-1105 as indicated in the P2 topline data, which reflects six-month sustained delivery, may render this product, if appr

Slide 21: Expanding Aerie Franchise: Japan
For Investor Use Expanding Aerie Franchise: Japan Phase 2 study successful topline results released in November 2019 First Phase 3 trial commenced in Japan in December 2020 Sources: IMS Analytics link at ex-manufacturer price level and Unit-April 2020. *TRx calculated from IQVIA unit data (1 month =

Slide 22: AR-13324-CS208 Japan Phase 2 Study Topline Results
AR-13324-CS208 Japan Phase 2 Study Topline Results 28-day prospective, double-masked, placebo-controlled, dose-ranging study of netarsudil efficacy and safety in Japanese subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT) Netarsudil 0.01%, 0.02% and 0.04% were efficacious, met prim

Slide 23: AR-13324-CS208 Japan Phase 2 Study Topline Results: IOP vs placebo
P<0.0001 vs. placebo at Week 4 for all dose levels1 0.02% achieved lowest mean diurnal IOP at Week 4 1. ANCOVA with MCMC imputation AR-13324-CS208 Japan Phase 2 Study Topline Results For Investor Use

Slide 24: Expanding Aerie Franchise: Europe
For Investor Use Expanding Aerie Franchise: Europe Marketing authorisation granted for Rhokiinsa® (Rhopressa®) in November 2019 and for Roclanda® (Rocklatan®) in January 2021 Mercury 3: Reported successful 90-day topline data in September 2020; Rocklatan® (known as Roclanda® in Europe) achieved non-

Slide 25: Summary Key Priorities
For Investor Use Summary Key Priorities Driving continued Rhopressa® and Rocklatan® volume growth in the U.S. Globalization Strategy Japan: Santen collaboration commencing and first Phase 3 trial underway Europe: Interest expressed from potential collaborators Ireland Manufacturing Facility approved
Source: SEC EDGAR · 8-K filed Jan 19, 2021
More decks from Aerie Pharmaceuticals Inc.
Investor Presentation (September 2022)30 slides · Sep 13, 2022
Merger or Acquisition (August 2022)30 slides · Aug 23, 2022
Investor Presentation (June 2022)30 slides · Jun 8, 2022
Investor Presentation (May 2022)28 slides · May 25, 2022
Investor Presentation (April 2022)25 slides · Apr 11, 2022
Investor Presentation (January 2022)33 slides · Jan 5, 2022